Category: Media Coverage

Note: When you click on media articles below, a new page will open indicating that you are leaving the Genprex, Inc. website and entering a third-party website not affiliated with Genprex Inc. or any of its affiliates. No information contained in a linked site has been endorsed or approved by Genprex, Inc. and Genprex, Inc. is not responsible for the content of such third-party websites.

Genprex Wins FDA Fast Track Status for its Oncoprex Therapy in Combination with AstraZeneca’s Tagrisso

Genprex Inc (NASDAQ:GNPX) announced that the US Food and Drug Administration has granted Fast Track Designation for its Oncoprex immunogene therapy to treat lung cancer.

Read More

FDA Grants Fast Track Designation to Oncoprex Combination for NSCLC

Oncoprex in combination with Tagrisso received fast track designation from the Food and Drug Administration to treat patients with non-small cell lung cancer.

Read More

FDA Grants Fast Track Designation to Gene Therapy Combination in EGFR-Mutant NSCLC

The FDA has granted a Fast Track Designation to the immune-gene therapy Oncoprex in combination with the EGFR inhibitor osimertinib (Tagrisso) for the treatment of patients with EGFR-mutant non–small cell lung cancer (NSCLC) who have progressed after treatment with osimertinib alone, according to a press release from Genprex, Inc, developer of the therapeutic.

Read More

In the money Nov. 25: $54M raised for drones, software, cancer-fighting drugs

Five companies in the past week reported more than $54 million in funding deals and securities offerings.

Read More

How Genprex took an abandoned pipeline drug and turned it into Oncoprex, an innovative treatment for non-small cell lung cancer

The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual.

Read More

How gene therapy is reprogramming the course of lung cancer

How gene therapy is reprogramming the course of lung cancer.

Read More

IPO alert: Cancer-fighting startup Genprex raises millions going public to fund new treatments

Lead product, Oncoprex, is an injectable treatment for lung cancer.

Read More

SPORE Grants Turn Into Hope for Patients

SPORE Grants Turn Into Hope for Patients.

Read More